source.wustl.edu
$15 million supports quest for personalized leukemia therapies | The Source | Washington University in St. Louis
Investigators at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $15 million grant to better understand the genetic changes that drive acute myeloid leukemia (AML), a deadly blood cancer, and predict patients’ responses to therapy. The findings also may enable investigators to develop more effective therapies tailored to patients, based on the genetic characteristics of their cancer cells.